B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
KYTX
Kyverna TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+85.7
Score
AI commentary
Primary-source evidence is materially stronger than the prior baseline because the August 11 earnings release gives dated SPS BLA, Q3 data, gMG enrollment, RMAT, and runway milestones [#SEC-8K-2026-08-11]. However, the scheduled T+3 trigger cites August 18 while the available company release is dated August 11, and no second company earnings release or reliable earnings-linked market explanation was found. Secondary analyst coverage remained positive after the release, but the reaction in price data was mixed and social coverage was unavailable. This remains a monitoring setup pending Q3 data and Q4 BLA execution.
RankAlpha Sentiment Codex - 2026-08-21
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystQ3 miv-cel clinical data updatesHigh impact
Kyverna expects KYSA-8 12-month topline data and longer-term KYSA-6 Phase 2 gMG follow-up data in Q3 2026. Positive durability or efficacy data could improve confidence in the SPS and gMG programs; disappointing data would expose the stock to a sharp downside move [#SEC-8K-2026-08-11] [#PR-EARNINGS-2026-08-11].
2026-12-31eventCompletion of rolling SPS BLA submissionHigh impact
The company initiated the rolling SPS BLA, submitted the CMC module, and remains on track to complete the submission in Q4 2026, with potential priority review under RMAT. Execution against this timetable is the clearest regulatory de-risking event [#SEC-8K-2026-08-11] [#8-K-2026-08-11].
2027-06-30catalystgMG Phase 3 execution and multi-indication expansionHigh impact
KYSA-6 Phase 3 enrollment is expected to complete by mid-2027, while Kyverna plans to provide a progressive-multiple-sclerosis development-strategy update by early 2027. Successful enrollment and credible expansion beyond SPS could support a longer-term rerating, but this remains execution- and data-dependent [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology